Verrica Q1 2026: Net revenue $5.0M; YCANTH units up 51% YoY; net loss $9.7M

Verrica Pharmaceuticals Inc.

2026-Q1 EPS reported -$0.45 vs consensus -$0.39 ▼ miss (-16.2%)

YCANTH dispensed units 15,302 (+12.1% QoQ, +51.3% YoY); net product revenue $4.3M (+16.2% QoQ, +25.4% YoY).
Total revenue $5.0M includes $0.7M license/collaboration revenue from Torii Japan launch.
Net loss $9.7M ($0.45 per share); non-GAAP net loss $8.8M ($0.41 per share).
Phase 3 common warts trial (COVE-2) >50% enrolled; second trial (COVE-3) expected mid-2026.
Appointed Chris Chapman as Chief Commercial Officer; Phase 2 VP-315 BCC data to be presented at SID May 13-16.

item 2.02item 9.01

Source: SEC EDGAR

accession 0001193125-26-219395

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.